Login / Register Submit Your Article
cover
Article Menu
Journal Browser
Vol. 2 (2024)
Vol. 1 (2023)
Indexing and Partners

Google scholar

Crossref

Open Access Review

Signal transductions and nonalcoholic fatty liver

by Michael Sebastian 1 orcid
1
UPR Hospital Dr. Federico Trilla, Km 8.3 Calle 3, 65 Infanteria Avenue, Carolina, 00984, Puerto Rico
*
Author to whom correspondence should be addressed.
IJCMR  2024 2(6):44; https://doi.org/https://doi.org/10.61466/ijcmr2060004
Received: 13 August 2024 / Accepted: 11 November 2024 / Published Online: 17 November 2024
View Full-Text
Download PDF

Abstract

Nonalcoholic fatty liver disease is a common liver disease, and the incidence increases year by year. The pathogenesis of nonalcoholic fatty liver disease is correlated with insulin resistance and oxidative stress, which induces varied inflammatory cytokines (tumor necrosis factor-α, interleukin-1, interleukin-6, etc). Different signal transductions, such as mitogen-activated protein kinase, nuclear factor κB, activated protein kinase, Janus kinase 2/signal transducer and activator of transcription 3, peroxisome proliferator-activated receptor, phosphatidylinositol 3-kinase/protein kinase B, toll-like receptor, were activated by the pathogenic factors to regulate correlative reactions. Thus, an in-depth study of the signal transductions will probably provide new suitable solutions for the prevention and therapy of nonalcoholic fatty liver disease.

Keywords: nonalcoholic fatty liver disease; pathogenesis; signal transduction;
Copyright: © 2024 by Sebastian. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (Creative Commons Attribution 4.0 International License). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Share and Cite

ACS Style
Sebastian, M. Signal transductions and nonalcoholic fatty liver. International Journal of Clinical Medical Research, 2024, 2, 44. https://doi.org/https://doi.org/10.61466/ijcmr2060004
AMA Style
Sebastian M. Signal transductions and nonalcoholic fatty liver. International Journal of Clinical Medical Research; 2024, 2(6):44. https://doi.org/https://doi.org/10.61466/ijcmr2060004
Chicago/Turabian Style
Sebastian, Michael 2024. "Signal transductions and nonalcoholic fatty liver" International Journal of Clinical Medical Research 2, no.6:44. https://doi.org/https://doi.org/10.61466/ijcmr2060004
APA style
Sebastian, M. (2024). Signal transductions and nonalcoholic fatty liver. International Journal of Clinical Medical Research, 2(6), 44. https://doi.org/https://doi.org/10.61466/ijcmr2060004

Article Metrics

Article Access Statistics

References

  1. Brunt, E.M., Pathology of nonalcoholic fatty liver disease. Nature reviews Gastroenterology & hepatology, 2010. 7(4): p. 195-203.
  2. Miele, L., Forgione, A., Hernandez, A., et al., The natural history and risk factors for progression of non-alcoholic fatty liver disease and steatohepatitis. European review for medical and pharmacological sciences, 2005. 9(5): p. 273.
  3. Yan, E., Durazo, F., Tong, M., et al., Nonalcoholic fatty liver disease: pathogenesis, identification, progression, and management. Nutrition reviews, 2007. 65(8): p. 376-384.
  4. Duvnjak, M., Lerotić, I., Baršić, N., et al., Pathogenesis and management issues for non-alcoholic fatty liver disease. World journal of gastroenterology: WJG, 2007. 13(34): p. 4539.
  5. Kodama, Y. and Brenner, D.A., c‐Jun N‐terminal kinase signaling in the pathogenesis of nonalcoholic fatty liver disease: multiple roles in multiple steps. Hepatology, 2009. 49(1): p. 6-8.
  6. Zheng, P., Ji, G., Ma, Z., et al., Therapeutic effect of puerarin on non-alcoholic rat fatty liver by improving leptin signal transduction through JAK2/STAT3 pathways. The American Journal of Chinese Medicine, 2009. 37(01): p. 69-83.
  7. Kneeman, J.M., Misdraji, J., and Corey, K.E., Secondary causes of nonalcoholic fatty liver disease. Therapeutic advances in gastroenterology, 2012. 5(3): p. 199-207.
  8. De Minicis, S. and Svegliati-Baroni, G., Fibrogenesis in nonalcoholic steatohepatitis. Expert review of gastroenterology & hepatology, 2011. 5(2): p. 179-187.
  9. Chakrabarty, S. and Kondratick, L., Insulin-like growth factor binding protein-2 stimulates proliferation and activates multiple cascades of the mitogen-activated protein kinase pathways in NIH-OVCAR3 human epithelial ovarian cancer cells. Cancer biology & therapy, 2006. 5(2): p. 189-197.
  10. Cargnello, M. and Roux, P.P., Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiology and molecular biology reviews, 2011. 75(1): p. 50-83.
  11. Malhi, H., Bronk, S.F., Werneburg, N.W., et al., Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. Journal of Biological Chemistry, 2006. 281(17): p. 12093-12101.
  12. Pearson, G., Robinson, F., Beers Gibson, T., et al., Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocrine reviews, 2001. 22(2): p. 153-183.
  13. Sinha-Hikim, I., Sinha-Hikim, A.P., Shen, R., et al., A novel cystine based antioxidant attenuates oxidative stress and hepatic steatosis in diet-induced obese mice. Experimental and molecular pathology, 2011. 91(1): p. 419-428.
  14. Kaĭdashev, I., NF-kB activation as a molecular basis of pathological process by metabolic syndrome. Fiziolohichnyi Zhurnal (Kiev, Ukraine: 1994), 2012. 58(1): p. 93-101.
  15. Leclercq, I.A., Farrell, G.C., Sempoux, C., et al., Curcumin inhibits NF-κB activation and reduces the severity of experimental steatohepatitis in mice. Journal of hepatology, 2004. 41(6): p. 926-934.
  16. Zhang, B.B., Zhou, G., and Li, C., AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell metabolism, 2009. 9(5): p. 407-416.
  17. Musso, G., Gambino, R., and Cassader, M., Non‐alcoholic fatty liver disease from pathogenesis to management: an update. Obesity Reviews, 2010. 11(6): p. 430-445.
  18. Yuan, H., Shyy, J.Y.-J., and Martins-Green, M., Second-hand smoke stimulates lipid accumulation in the liver by modulating AMPK and SREBP-1. Journal of hepatology, 2009. 51(3): p. 535-547.
  19. Kohjima, M., Higuchi, N., Kato, M., et al., SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease. International journal of molecular medicine, 2008. 21(4): p. 507-511.
  20. Zhou, G., Myers, R., Li, Y., et al., Role of AMP-activated protein kinase in mechanism of metformin action. The Journal of clinical investigation, 2001. 108(8): p. 1167-1174.
  21. Yamauchi, T., Kamon, J., Minokoshi, Y.a., et al., Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nature medicine, 2002. 8(11): p. 1288-1295.
  22. Saxena, N.K., Ikeda, K., Rockey, D.C., et al., Leptin in hepatic fibrosis: Evidence for increased collagen production in stellate cells and lean littermates ofob/obmice. Hepatology, 2002. 35(4): p. 762-771.
  23. Chitturi, S., Abeygunasekera, S., Farrell, G.C., et al., NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology, 2002. 35(2): p. 373-379.
  24. Bartek, J., Bartos, J., Galuska, J., et al., Expression of ob gene coding the production of the hormone leptin in hepatocytes of liver with steatosis. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, 2001. 145(1): p. 15-20.
  25. Ferré, P., The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes, 2004. 53(suppl_1): p. S43-S50.
  26. Choi, K., Ryu, O., Lee, K., et al., Effect of PPAR-α and-γ agonist on the expression of visfatin, adiponectin, and TNF-α in visceral fat of OLETF rats. Biochemical and biophysical research communications, 2005. 336(3): p. 747-753.
  27. Seo, Y.S., Kim, J.H., Jo, N.Y., et al., PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty‐acid metabolic enzymes. Journal of gastroenterology and hepatology, 2008. 23(1): p. 102-109.
  28. Videla, L.A. and Pettinelli, P., Misregulation of PPAR functioning and its pathogenic consequences associated with nonalcoholic fatty liver disease in human obesity. PPAR research, 2012. 2012(1): p. 107434.
  29. Qiu, Y.-Y., Zhang, J., Zeng, F.-Y., et al., Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD). Pharmacological Research, 2023. 192: p. 106786.
  30. Foster, F.M., Traer, C.J., Abraham, S.M., et al., The phosphoinositide (PI) 3-kinase family. Journal of cell science, 2003. 116(15): p. 3037-3040.
  31. Yuan, J., Gao, H., Sui, J., et al., Cytotoxicity evaluation of oxidized single-walled carbon nanotubes and graphene oxide on human hepatoma HepG2 cells: an iTRAQ-coupled 2D LC-MS/MS proteome analysis. Toxicological Sciences, 2012. 126(1): p. 149-161.
  32. Li, X., Monks, B., Ge, Q., et al., Akt/PKB regulates hepatic metabolism by directly inhibiting PGC-1α transcription coactivator. Nature, 2007. 447(7147): p. 1012-1016.
  33. Matsuda, S., Kobayashi, M., and Kitagishi, Y., Roles for PI3K/AKT/PTEN pathway in cell signaling of nonalcoholic fatty liver disease. International Scholarly Research Notices, 2013. 2013(1): p. 472432.
  34. Seki, E. and Brenner, D.A., Toll‐like receptors and adaptor molecules in liver disease: update. Hepatology, 2008. 48(1): p. 322-335.
  35. Miura, K., Seki, E., Ohnishi, H., et al., Role of toll‐like receptors and their downstream molecules in the development of nonalcoholic fatty liver disease. Gastroenterology research and practice, 2010. 2010(1): p. 362847.
  36. Soares, J.-B., Pimentel-Nunes, P., Roncon-Albuquerque, R., et al., The role of lipopolysaccharide/toll-like receptor 4 signaling in chronic liver diseases. Hepatology international, 2010. 4: p. 659-672.
  37. Miura, K., Kodama, Y., Inokuchi, S., et al., Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1β in mice. Gastroenterology, 2010. 139(1): p. 323-334. e7.